7,606.87

+26.80

+0.35%

52,276.11

+505.80

+0.98%

25,516.87

+79.87

+0.31%

2,838.02

+26.18

+0.93%

4.8820

-0.0470

-0.95%

19.04

-0.38

-1.96%

3,974.00

+75.10

+1.93%

76,936.74

-917.25

-1.18%

Crude Oil Dec 26

96.62

-7.50

-7.20%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCQB - Delayed Quote USD

Sona Nanotech Inc. (SNANF)

0.2000 0.0000 (0.00%)

As of October 30 at 4:00:00 PM EDT. Market Open.

Loading Chart for SNANF

Chart Range Bar

Interval:

In partnership with ChartIQ

Sona Nanotech Announces Chief Technology Officer and Annual Options Grants

Sona Nanotech Announces Chief Technology Officer and Annual Options Grants

Life Sciences Virtual Investor Forum Agenda Announced

Life Sciences Virtual Investor Forum Agenda Announced

Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th

Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th

Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds

Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds

SONA NANOTECH TO ARRANGE PRIVATE PLACEMENT FINANCING

SONA NANOTECH TO ARRANGE PRIVATE PLACEMENT FINANCING

Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors

Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors

Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma

Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma

Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences

Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences

Sona Nanotech appoints two oncologists to scientific advisory board

Sona Nanotech appoints two oncologists to scientific advisory board

Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies

Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Mobilize your Website

View Site in Mobile | Classic

Share by: